Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Grace Therapeutics, Inc. (GRCE)
USD2.44
-0.03 (-1.02%)
US NASDAQ Healthcare Biotechnology
Address
103 Carnegie Center 8540
Princeton, NJ, US
Princeton, NJ, US
CEO
Prashant Kohli
Website
acastipharma.com
IPO
2012-02-07
CIK 1444192 ISIN US00439U1043
Also trades on
NASDAQ Capital Market · ACST (USD)
NASDAQ Global Market · GRCE (USD)
Toronto Stock Exchange Ventures · ACST.V (CAD)
Description
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD2.44
-0.03 (-1.02%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
722.4K
Beta
0.36
Float Shares
11.25M
Free Float %
72.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +7.21% | +3.03% | +10.70% | -45.66% | -30.00% | -31.21% | -20.67% | -20.93% | -20.93% | -20.93% | -20.93% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Buy
Price Targets & DCF
Current price
2.44
Low
4.00
+64.3%
Consensus
4.00
+64.3%
Median
4.00
+64.3%
High
4.00
+64.3%
DCF (Unlevered)
0.70
-71.3%
DCF (Levered)
0.73
-70.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-06 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
4.00
+64.3%
|
| Last Year | 1 |
4.00
+64.3%
|
| All Time | 1 |
4.00
+64.3%
|
Quality scores
Altman Z-Score
5.46
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+58.4% ★ Q1'26: -213.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-23.6% Q1'26: -15.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+36.6% Q1'26: +17.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2022 actual |
Mar 2025 actual |
Mar 2026 2 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
Mar 2028 2 Rev. Ana. 2 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
300.5K
est: 475.7K (-36.8%)
|
39.2K
est: 469.1K (-91.6%)
|
—
est: 35.1K (-100.0%)
|
—
est: 15.85M (-100.0%)
|
—
|
450.0K
434.8K – 465.2K
|
5.00M
4.23M – 5.77M
+1,011.1% YoY
|
23.20M
19.63M – 26.77M
+364.0% YoY
|
100.00M
84.62M – 115.38M
+331.0% YoY
|
140.00M
118.46M – 161.54M
+40.0% YoY
|
| EBITDA |
-8.04M
est: 285.4K (-2,917.0%)
|
-2.89M
est: 281.5K (-1,128.2%)
|
-5.96M
est: 21.1K (-28,372.3%)
|
-19.17M
est: 9.51M (-301.5%)
|
-23.74M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-9.91M
est: 285.4K (-3,570.8%)
|
-4.66M
est: 281.5K (-1,756.1%)
|
-7.88M
est: 21.1K (-37,509.5%)
|
-19.17M
est: 9.51M (-301.5%)
|
-23.75M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-1.32M
est: -551.01M (+99.8%)
|
-4.66M
est: -390.76M (+98.8%)
|
-7.91M
est: -346.86M (+97.7%)
|
-12.27M
est: -10.15M (-20.8%)
|
-13.63M
est: -13.98M (+2.6%)
|
-13.67M
-16.35M – -10.90M
+2.3% YoY
|
-10.24M
-12.28M – -8.19M
+25.1% YoY
|
-1.32M
-1.50M – -1.14M
+87.1% YoY
|
26.42M
21.13M – 31.70M
+2,100.0% YoY
|
39.63M
31.70M – 47.55M
+50.0% YoY
|
| SGA |
2.86M
est: 3.61M (-20.9%)
|
1.51M
est: 3.56M (-57.6%)
|
576.0K
est: 266.6K (+116.0%)
|
12.22M
est: 120.32M (-89.8%)
|
10.20M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-10.66
est: -45.59 (+76.6%)
|
-29.48
est: -32.33 (+8.8%)
|
-34.22
est: -28.70 (-19.2%)
|
-2.02
est: -0.84 (-140.5%)
|
-1.13
est: -1.16 (+2.8%)
|
-0.83
-0.99 – -0.66
+29.0% YoY
|
-0.62
-0.74 – -0.50
+24.8% YoY
|
-0.08
-0.09 – -0.07
+87.1% YoY
|
1.60
1.28 – 1.92
+2,100.0% YoY
|
2.40
1.92 – 2.88
+50.0% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-24 | TD Cowen | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-18 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-06-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-06-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-06-15 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-06-12 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-06-11 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-06-10 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-06-09 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-06-08 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-06-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-06-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-06-03 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-06-02 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-06-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-26 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-19 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-18 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-14 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-10.13M
OE per share TTM
-0.65
Owner's Yield
-25.77%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
1,954.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
36
Total invested
19.74M
Insider transactions (90d)
0
Beneficial owners (>5%)
10
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ACUITAS GROUP HOLDINGS, LLC | 8.65M | 10.58% | 8.65M | — | 8.65M | — | CO | CALIFORNIA | 2019-07-19 | ↗ |
| 2 | Terren S. Peizer | 8.65M | 10.58% | 8.65M | — | 8.65M | — | IN | United States of America | 2019-07-19 | ↗ |
| 3 | ADAR1 Capital Management, LLC | 1.72M | 9.90% | 1.72M | 1.72M | 1.72M | — | IA, OO | TEXAS | 2026-05-15 | ↗ |
| 4 | Nantahala Capital Management, LLC | 1.59M | 9.99% | 1.59M | 1.59M | 1.59M | — | IA | MASSACHUSETTS | 2026-02-13 | ↗ |
| 5 | ADAR1 Capital Management GP, LLC | 959.6K | 10.20% | — | 959.6K | — | 959.6K | OO | Citizenship or place of organization | 2024-07-10 | ↗ |
| 6 | Daniel Schneeberger | 959.6K | 10.20% | — | 959.6K | — | 959.6K | IN | Citizenship or place of organization | 2024-07-10 | ↗ |
| 7 | Orin Hirschman | 814.0K | 4.90% | — | — | — | — | HC, IN | UNITED STATES | 2026-04-27 | ↗ |
| 8 | 27-4413262 | 567.8K | 6.00% | 567.8K | — | 567.8K | — | OO | Maryland | 2024-04-09 | ↗ |
| 9 | Identification Nos. of above persons (. | 567.8K | 6.00% | 567.8K | — | 567.8K | — | IN | States | 2024-04-09 | ↗ |
| 10 | BANK OF AMERICA CORPORATION56-0906609 | 494.7K | 5.30% | — | 494.7K | — | 494.7K | HC | — | 2024-02-13 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
36
+14 vs prev Q
New positions
19
Closed positions
6
Increased
25
Reduced
4
Put/Call ratio
1.23
Calls held
50.6K
Puts held
62.2K
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | NANTAHALA CAPITAL MANAGEMENT, LLC | 1.18M +— (+0.0%) | 4.08M +565.5K (+16.1%) | 6.96% -0.441 pp | 0.13% +0.013 pp | USD2.28 +51.8% | 4 qtrs — |
| 2 | AIGH CAPITAL MANAGEMENT LLC | 907.2K +— (+0.0%) | 3.15M +447.0K (+16.6%) | 5.70% +0.000 pp | 0.76% +0.001 pp | USD2.86 +21.0% | 5 qtrs — |
| 3 | ADAR1 CAPITAL MANAGEMENT, LLC | 642.0K +291.5K (+83.2%) | 2.22M +1.2M (+112.9%) | 3.79% +1.591 pp | 0.16% +0.065 pp | USD3.21 +7.8% | 6 qtrs — |
| 4 | BANK OF AMERICA CORP /DE/ | 494.7K +— (+0.0%) | 1.71M +238.9K (+16.2%) | 2.92% -0.185 pp | 0.00% +0.000 pp | USD3.74 -7.5% | 5 qtrs — |
| 5 | VANGUARD GROUP INC | 424.0K +14.9K (+3.6%) | 1.48M +264.7K (+21.8%) | 2.50% -0.065 pp | 0.00% +0.000 pp | USD3.35 +3.3% | 5 qtrs — |
| 6 | CERITY PARTNERS LLC | 422.7K +422.7K (+100.0%) | 1.46M +1.5M (+100.0%) | 2.65% +2.655 pp | 0.00% +0.002 pp | USD3.46 +0.0% | 1 qtrs NEW |
| 7 | RENAISSANCE TECHNOLOGIES LLC | 129.8K +45.2K (+53.5%) | 449.0K +197.3K (+78.4%) | 0.77% +0.235 pp | 0.00% +0.000 pp | USD3.31 +4.5% | 5 qtrs — |
| 8 | CITADEL ADVISORS LLC | 42.3K +15.0K (+55.1%) | 147.6K +66.6K (+82.3%) | 0.25% +0.079 pp | 0.00% +0.000 pp | USD3.28 +5.5% | 5 qtrs — |
| 9 | XTX TOPCO LTD | 30.3K +30.3K (+100.0%) | 105.6K +105.6K (+100.0%) | 0.18% +0.179 pp | 0.00% +0.003 pp | USD3.46 +0.0% | 1 qtrs NEW |
| 10 | MORGAN STANLEY | 25.4K +23.6K (+1,277.1%) | 88.1K +82.5K (+1,500.6%) | 0.15% +0.139 pp | 0.00% +0.000 pp | USD3.48 -0.6% | 5 qtrs — |
| 11 | GSA CAPITAL PARTNERS LLP | 13.8K +13.8K (+100.0%) | 48.0K +48.0K (+100.0%) | 0.09% +0.087 pp | 0.00% +0.004 pp | USD3.46 +0.0% | 1 qtrs NEW |
| 12 | STRATOS WEALTH PARTNERS, LTD. | 11.2K +11.2K (+100.0%) | 38.7K +38.7K (+100.0%) | 0.07% +0.070 pp | 0.00% +0.000 pp | USD3.46 +0.0% | 1 qtrs NEW |
| 13 | NATIONAL BANK OF CANADA /FI/ | 2.7K +— (+0.0%) | 9.4K +1.3K (+16.6%) | 0.02% -0.001 pp | 0.00% +0.000 pp | USD3.74 -7.5% | 5 qtrs — |
| 14 | TOWER RESEARCH CAPITAL LLC (TRC) | 1.9K +335.0 (+20.8%) | 6.7K +1.9K (+40.4%) | 0.01% +0.001 pp | 0.00% +0.000 pp | USD3.02 +14.6% | 5 qtrs — |
| 15 | BNP PARIBAS ARBITRAGE, SNC | 600.00 +600.0 (+100.0%) | 2.1K +2.1K (+100.0%) | 0.00% +0.004 pp | 0.00% +0.000 pp | USD3.46 +0.0% | 1 qtrs NEW |
| 16 | ROYAL BANK OF CANADA | 543.00 -28.0 (-4.9%) | 2.0K +— (+0.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD3.70 -6.5% | 5 qtrs — |
| 17 | ACTIVEST WEALTH MANAGEMENT | 104.00 +— (+0.0%) | 360.00 +50.0 (+16.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.73 -7.2% | 5 qtrs — |
| 18 | SBI SECURITIES CO., LTD. | 101.00 +— (+0.0%) | 349.00 +48.0 (+15.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.28 +51.8% | 5 qtrs — |
| 19 | STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 41.00 +— (+0.0%) | 142.00 +20.0 (+16.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.95 +17.3% | 3 qtrs — |
| 20 | FLAGSHIP HARBOR ADVISORS, LLC | 2.00 +2.0 (+100.0%) | 7.00 +7.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.00 +15.3% | 1 qtrs NEW |
| 21 | NBC SECURITIES, INC. | 2.00 +— (+0.0%) | 6.00 +1.0 (+20.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.50 +38.4% | 2 qtrs — |
| 22 | FEDERATION DES CAISSES DESJARDINS DU QUEBEC | 1.00 +— (+0.0%) | 3.00 +— (+0.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.00 +15.3% | 5 qtrs — |
| 23 | STONEPINE CAPITAL MANAGEMENT, LLC | — -211.0K (-100.0%) | — -628.2K (-100.0%) | 0.00% -1.325 pp | 0.00% -0.511 pp | USD— | 4 qtrs SOLD |
| 24 | SEACREST WEALTH MANAGEMENT, LLC | — -14.0K (-100.0%) | — -42.0K (-100.0%) | 0.00% -0.088 pp | 0.00% -0.004 pp | USD— | 2 qtrs SOLD |
| 25 | CITIGROUP INC | — -2.8K (-100.0%) | — -8.2K (-100.0%) | 0.00% -0.017 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 26 | MILLINGTON FINANCIAL ADVISORS, LLC | — -20.0K (-100.0%) | — -59.7K (-100.0%) | 0.00% -0.126 pp | 0.00% -0.029 pp | USD— | 3 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 11 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.01% | 86.2K | 0.60% |
| 2 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 2.2K | 0.03% |
| 3 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 6.0K | 0.17% |
| 4 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 442.19 | 0.17% |
| 5 | Vanguard Total Stock Market ETF VTI | 0.00% | 1.02M | 0.03% |
| 6 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 2.2K | 0.22% |
| 7 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 1.2K | 0.22% |
| 8 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 493.12 | 0.22% |
| 9 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 54.35 | 0.22% |
| 10 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 7.64 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-08 | NEUGEBOREN EDWARD | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 3.80 | 38.0K | 10,000 | D | ↗ |
| 2026-01-08 | Kottayil George | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 3.80 | 38.0K | 10,000 | D | ↗ |
| 2026-01-08 | Kavuru Vimal | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 3.80 | 38.0K | 10,000 | D | ↗ |
| 2026-01-08 | DAVIS A BRIAN | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 3.80 | 38.0K | 10,000 | D | ↗ |
| 2025-05-09 | NEUGEBOREN EDWARD | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 2.72 | 27.2K | 10,000 | D | ↗ |
| 2025-05-09 | Kottayil George | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 2.72 | 27.2K | 10,000 | D | ↗ |
| 2025-05-09 | Kavuru Vimal | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 2.72 | 27.2K | 10,000 | D | ↗ |
| 2025-05-09 | DAVIS A BRIAN | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 2.72 | 27.2K | 10,000 | D | ↗ |
| 2025-04-14 | Macdonald R. Loch | Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 2.08 | 83.2K | 40,000 | D | ↗ |
| 2025-04-14 | Kumar Amresh | Officer | A-Award | A | Stock Option (Right to Buy) | 30,000 | 2.08 | 62.4K | 30,000 | D | ↗ |
| 2025-04-14 | Kohli Prashant | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 225,400 | 2.08 | 468.8K | 225,400 | D | ↗ |
| 2025-04-14 | DelAversano Robert J | Officer | A-Award | A | Stock Option (Right to Buy) | 20,130 | 2.08 | 41.9K | 20,130 | D | ↗ |
| 2025-04-14 | D'Andrea Carrie | Officer | A-Award | A | Stock Option (Right to Buy) | 30,000 | 2.08 | 62.4K | 30,000 | D | ↗ |
Executive team
Top executives
Shares Outstanding
15.47M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Prashant Kohli Chief Executive Officer | 500.0K | — | — | 324.6K | 250.0K | — | 1.07M | 30.21% | ↗ |
| 2 | 2025 | Amresh Kumar Vice President, Program Management | 286.0K | — | — | 49.8K | 85.8K | — | 421.6K | 11.80% | ↗ |
| 3 | 2025 | Carrie D’Andrea Vice President, Clinical Operations | 286.0K | — | — | 49.8K | 85.8K | — | 421.6K | 11.80% | ↗ |
| 4 | 2024 | Prashant Kohli Chief Executive Officer | 400.0K | — | — | 387.7K | 200.0K | — | 987.6K | 39.25% | ↗ |
| 5 | 2024 | Carrie D’Andrea Vice President, Clinical Operations | 248.3K | — | — | 52.3K | 82.5K | — | 383.0K | 13.64% | ↗ |
| 6 | 2024 | Amresh Kumar Vice President, Program Management | 243.3K | — | — | 52.3K | 82.5K | — | 378.0K | 13.82% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Prashant Kohli | Chief Executive Officer & Director | 750.0K | male |
| Amresh Kumar | Vice President of Program Management | 371.8K | male |
| Carrie D'Andrea | Vice President of Clinical Operations | 371.8K | female |
| R. Loch MacDonald | Member of Scientific Advisory Board & Chief Medical Officer | — | — |
| Robert J. DelAversano | Vice President of Finance and Principal Financial & Accounting Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GRCE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
